45 results on '"Griffiths, Anthony"'
Search Results
2. 2022 taxonomic update of phylum Negarnaviricota (Riboviria: Orthornavirae), including the large orders Bunyavirales and Mononegavirales
- Author
-
Kuhn, Jens H., Adkins, Scott, Alkhovsky, Sergey V., Avšič-Županc, Tatjana, Ayllón, María A., Bahl, Justin, Balkema-Buschmann, Anne, Ballinger, Matthew J., Bandte, Martina, Beer, Martin, Bejerman, Nicolas, Bergeron, Éric, Biedenkopf, Nadine, Bigarré, Laurent, Blair, Carol D., Blasdell, Kim R., Bradfute, Steven B., Briese, Thomas, Brown, Paul A., Bruggmann, Rémy, Buchholz, Ursula J., Buchmeier, Michael J., Bukreyev, Alexander, Burt, Felicity, Büttner, Carmen, Calisher, Charles H., Candresse, Thierry, Carson, Jeremy, Casas, Inmaculada, Chandran, Kartik, Charrel, Rémi N., Chiaki, Yuya, Crane, Anya, Crane, Mark, Dacheux, Laurent, Bó, Elena Dal, de la Torre, Juan Carlos, de Lamballerie, Xavier, de Souza, William M., de Swart, Rik L., Dheilly, Nolwenn M., Di Paola, Nicholas, Di Serio, Francesco, Dietzgen, Ralf G., Digiaro, Michele, Drexler, J. Felix, Duprex, W. Paul, Dürrwald, Ralf, Easton, Andrew J., Elbeaino, Toufic, Ergünay, Koray, Feng, Guozhong, Feuvrier, Claudette, Firth, Andrew E., Fooks, Anthony R., Formenty, Pierre B. H., Freitas-Astúa, Juliana, Gago-Zachert, Selma, García, María Laura, García-Sastre, Adolfo, Garrison, Aura R., Godwin, Scott E., Gonzalez, Jean-Paul J., de Bellocq, Joëlle Goüy, Griffiths, Anthony, Groschup, Martin H., Günther, Stephan, Hammond, John, Hepojoki, Jussi, Hierweger, Melanie M., Hongō, Seiji, Horie, Masayuki, Horikawa, Hidenori, Hughes, Holly R., Hume, Adam J., Hyndman, Timothy H., Jiāng, Dàohóng, Jonson, Gilda B., Junglen, Sandra, Kadono, Fujio, Karlin, David G., Klempa, Boris, Klingström, Jonas, Koch, Michel C., Kondō, Hideki, Koonin, Eugene V., Krásová, Jarmila, Krupovic, Mart, Kubota, Kenji, Kuzmin, Ivan V., Laenen, Lies, Lambert, Amy J., Lǐ, Jiànróng, Li, Jun-Min, Lieffrig, François, Lukashevich, Igor S., Luo, Dongsheng, Maes, Piet, Marklewitz, Marco, Marshall, Sergio H., Marzano, Shin-Yi L., McCauley, John W., Mirazimi, Ali, Mohr, Peter G., Moody, Nick J. G., Morita, Yasuaki, Morrison, Richard N., Mühlberger, Elke, Naidu, Rayapati, Natsuaki, Tomohide, Navarro, José A., Neriya, Yutaro, Netesov, Sergey V., Neumann, Gabriele, Nowotny, Norbert, Ochoa-Corona, Francisco M., Palacios, Gustavo, Pallandre, Laurane, Pallás, Vicente, Papa, Anna, Paraskevopoulou, Sofia, Parrish, Colin R., Pauvolid-Corrêa, Alex, Pawęska, Janusz T., Pérez, Daniel R., Pfaff, Florian, Plemper, Richard K., Postler, Thomas S., Pozet, Françoise, Radoshitzky, Sheli R., Ramos-González, Pedro L., Rehanek, Marius, Resende, Renato O., Reyes, Carina A., Romanowski, Víctor, Rubbenstroth, Dennis, Rubino, Luisa, Rumbou, Artemis, Runstadler, Jonathan A., Rupp, Melanie, Sabanadzovic, Sead, Sasaya, Takahide, Schmidt-Posthaus, Heike, Schwemmle, Martin, Seuberlich, Torsten, Sharpe, Stephen R., Shi, Mang, Sironi, Manuela, Smither, Sophie, Song, Jin-Won, Spann, Kirsten M., Spengler, Jessica R., Stenglein, Mark D., Takada, Ayato, Tesh, Robert B., Těšíková, Jana, Thornburg, Natalie J., Tischler, Nicole D., Tomitaka, Yasuhiro, Tomonaga, Keizō, Tordo, Noël, Tsunekawa, Kenta, Turina, Massimo, Tzanetakis, Ioannis E., Vaira, Anna Maria, van den Hoogen, Bernadette, Vanmechelen, Bert, Vasilakis, Nikos, Verbeek, Martin, von Bargen, Susanne, Wada, Jiro, Wahl, Victoria, Walker, Peter J., Whitfield, Anna E., Williams, John V., Wolf, Yuri I., Yamasaki, Junki, Yanagisawa, Hironobu, Ye, Gongyin, Zhang, Yong-Zhen, and Økland, Arnfinn Lodden
- Published
- 2022
- Full Text
- View/download PDF
3. Renaming of genera Ebolavirus and Marburgvirus to Orthoebolavirus and Orthomarburgvirus, respectively, and introduction of binomial species names within family Filoviridae
- Author
-
Biedenkopf, Nadine, Bukreyev, Alexander, Chandran, Kartik, Di Paola, Nicholas, Formenty, Pierre B. H., Griffiths, Anthony, Hume, Adam J., Mühlberger, Elke, Netesov, Sergey V., Palacios, Gustavo, Pawęska, Janusz T., Smither, Sophie, Takada, Ayato, Wahl, Victoria, and Kuhn, Jens H.
- Published
- 2023
- Full Text
- View/download PDF
4. Highly efficient and selective partial reduction of nitroarenes to N-arylhydroxylamines catalysed by phosphine oxide-decorated polymer immobilized ionic liquid stabilized ruthenium nanoparticles
- Author
-
Paterson, Reece, Alharbi, Husam Y., Wills, Corinne, Chamberlain, Thomas W., Bourne, Richard A., Griffiths, Anthony, Collins, Sean M., Wu, Kejun, Simmons, Matthew D., Menzel, Robert, Massey, Alexander F., Knight, Julian G., and Doherty, Simon
- Published
- 2023
- Full Text
- View/download PDF
5. Secondary structural ensembles of the SARS-CoV-2 RNA genome in infected cells
- Author
-
Lan, Tammy C. T., Allan, Matty F., Malsick, Lauren E., Woo, Jia Z., Zhu, Chi, Zhang, Fengrui, Khandwala, Stuti, Nyeo, Sherry S. Y., Sun, Yu, Guo, Junjie U., Bathe, Mark, Näär, Anders, Griffiths, Anthony, and Rouskin, Silvi
- Published
- 2022
- Full Text
- View/download PDF
6. IgG-like bispecific antibodies with potent and synergistic neutralization against circulating SARS-CoV-2 variants of concern
- Author
-
Chang, Matthew R., Tomasovic, Luke, Kuzmina, Natalia A., Ronk, Adam J., Byrne, Patrick O., Johnson, Rebecca, Storm, Nadia, Olmedillas, Eduardo, Hou, Yixuan J., Schäfer, Alexandra, Leist, Sarah R., Tse, Longping V., Ke, Hanzhong, Coherd, Christian, Nguyen, Katrina, Kamkaew, Maliwan, Honko, Anna, Zhu, Quan, Alter, Galit, Saphire, Erica Ollmann, McLellan, Jason S., Griffiths, Anthony, Baric, Ralph S., Bukreyev, Alexander, and Marasco, Wayne A.
- Published
- 2022
- Full Text
- View/download PDF
7. 2021 Taxonomic update of phylum Negarnaviricota (Riboviria: Orthornavirae), including the large orders Bunyavirales and Mononegavirales
- Author
-
Kuhn, Jens H., Adkins, Scott, Agwanda, Bernard R., Al Kubrusli, Rim, Alkhovsky, Sergey V., Amarasinghe, Gaya K., Avšič-Županc, Tatjana, Ayllón, María A., Bahl, Justin, Balkema-Buschmann, Anne, Ballinger, Matthew J., Basler, Christopher F., Bavari, Sina, Beer, Martin, Bejerman, Nicolas, Bennett, Andrew J., Bente, Dennis A., Bergeron, Éric, Bird, Brian H., Blair, Carol D., Blasdell, Kim R., Blystad, Dag-Ragnar, Bojko, Jamie, Borth, Wayne B., Bradfute, Steven, Breyta, Rachel, Briese, Thomas, Brown, Paul A., Brown, Judith K., Buchholz, Ursula J., Buchmeier, Michael J., Bukreyev, Alexander, Burt, Felicity, Büttner, Carmen, Calisher, Charles H., Cao, Mengji, Casas, Inmaculada, Chandran, Kartik, Charrel, Rémi N., Cheng, Qi, Chiaki, Yuya, Chiapello, Marco, Choi, Il-Ryong, Ciuffo, Marina, Clegg, J. Christopher S., Crozier, Ian, Dal Bó, Elena, de la Torre, Juan Carlos, de Lamballerie, Xavier, de Swart, Rik L., Debat, Humberto, Dheilly, Nolwenn M., Di Cicco, Emiliano, Di Paola, Nicholas, Di Serio, Francesco, Dietzgen, Ralf G., Digiaro, Michele, Dolnik, Olga, Drebot, Michael A., Drexler, J. Felix, Dundon, William G., Duprex, W. Paul, Dürrwald, Ralf, Dye, John M., Easton, Andrew J., Ebihara, Hideki, Elbeaino, Toufic, Ergünay, Koray, Ferguson, Hugh W., Fooks, Anthony R., Forgia, Marco, Formenty, Pierre B. H., Fránová, Jana, Freitas-Astúa, Juliana, Fu, Jingjing, Fürl, Stephanie, Gago-Zachert, Selma, Gāo, George Fú, García, María Laura, García-Sastre, Adolfo, Garrison, Aura R., Gaskin, Thomas, Gonzalez, Jean-Paul J., Griffiths, Anthony, Goldberg, Tony L., Groschup, Martin H., Günther, Stephan, Hall, Roy A., Hammond, John, Han, Tong, Hepojoki, Jussi, Hewson, Roger, Hong, Jiang, Hong, Ni, Hongo, Seiji, Horie, Masayuki, Hu, John S., Hu, Tao, Hughes, Holly R., Hüttner, Florian, Hyndman, Timothy H., Ilyas, M., Jalkanen, Risto, Jiāng, Dàohóng, Jonson, Gilda B., Junglen, Sandra, Kadono, Fujio, Kaukinen, Karia H., Kawate, Michael, Klempa, Boris, Klingström, Jonas, Kobinger, Gary, Koloniuk, Igor, Kondō, Hideki, Koonin, Eugene V., Krupovic, Mart, Kubota, Kenji, Kurath, Gael, Laenen, Lies, Lambert, Amy J., Langevin, Stanley L., Lee, Benhur, Lefkowitz, Elliot J., Leroy, Eric M., Li, Shaorong, Li, Longhui, Lǐ, Jiànróng, Liu, Huazhen, Lukashevich, Igor S., Maes, Piet, de Souza, William Marciel, Marklewitz, Marco, Marshall, Sergio H., Marzano, Shin-Yi L., Massart, Sebastien, McCauley, John W., Melzer, Michael, Mielke-Ehret, Nicole, Miller, Kristina M., Ming, Tobi J., Mirazimi, Ali, Mordecai, Gideon J., Mühlbach, Hans-Peter, Mühlberger, Elke, Naidu, Rayapati, Natsuaki, Tomohide, Navarro, José A., Netesov, Sergey V., Neumann, Gabriele, Nowotny, Norbert, Nunes, Márcio R. T., Olmedo-Velarde, Alejandro, Palacios, Gustavo, Pallás, Vicente, Pályi, Bernadett, Papa, Anna, Paraskevopoulou, Sofia, Park, Adam C., Parrish, Colin R., Patterson, David A., Pauvolid-Corrêa, Alex, Pawęska, Janusz T., Payne, Susan, Peracchio, Carlotta, Pérez, Daniel R., Postler, Thomas S., Qi, Liying, Radoshitzky, Sheli R., Resende, Renato O., Reyes, Carina A., Rima, Bertus K., Luna, Gabriel Robles, Romanowski, Víctor, Rota, Paul, Rubbenstroth, Dennis, Rubino, Luisa, Runstadler, Jonathan A., Sabanadzovic, Sead, Sall, Amadou Alpha, Salvato, Maria S., Sang, Rosemary, Sasaya, Takahide, Schulze, Angela D., Schwemmle, Martin, Shi, Mang, Shí, Xiǎohóng, Shí, Zhènglì, Shimomoto, Yoshifumi, Shirako, Yukio, Siddell, Stuart G., Simmonds, Peter, Sironi, Manuela, Smagghe, Guy, Smither, Sophie, Song, Jin-Won, Spann, Kirsten, Spengler, Jessica R., Stenglein, Mark D., Stone, David M., Sugano, Jari, Suttle, Curtis A., Tabata, Amy, Takada, Ayato, Takeuchi, Shigeharu, Tchouassi, David P., Teffer, Amy, Tesh, Robert B., Thornburg, Natalie J., Tomitaka, Yasuhiro, Tomonaga, Keizō, Tordo, Noël, Torto, Baldwyn, Towner, Jonathan S., Tsuda, Shinya, Tu, Changchun, Turina, Massimo, Tzanetakis, Ioannis E., Uchida, Janice, Usugi, Tomio, Vaira, Anna Maria, Vallino, Marta, van den Hoogen, Bernadette, Varsani, Arvind, Vasilakis, Nikos, Verbeek, Martin, von Bargen, Susanne, Wada, Jiro, Wahl, Victoria, Walker, Peter J., Wang, Lin-Fa, Wang, Guoping, Wang, Yanxiang, Wang, Yaqin, Waqas, Muhammad, Wèi, Tàiyún, Wen, Shaohua, Whitfield, Anna E., Williams, John V., Wolf, Yuri I., Wu, Jiangxiang, Xu, Lei, Yanagisawa, Hironobu, Yang, Caixia, Yang, Zuokun, Zerbini, F. Murilo, Zhai, Lifeng, Zhang, Yong-Zhen, Zhang, Song, Zhang, Jinguo, Zhang, Zhe, and Zhou, Xueping
- Published
- 2021
- Full Text
- View/download PDF
8. Correction to: 2021 Taxonomic update of phylum Negarnaviricota (Riboviria: Orthornavirae), including the large orders Bunyavirales and Mononegavirales
- Author
-
Kuhn, Jens H., Adkins, Scott, Agwanda, Bernard R., Al Kubrusli, Rim, Alkhovsky, Sergey V., Amarasinghe, Gaya K., Avšič-Županc, Tatjana, Ayllón, María A., Bahl, Justin, Balkema-Buschmann, Anne, Ballinger, Matthew J., Basler, Christopher F., Bavari, Sina, Beer, Martin, Bejerman, Nicolas, Bennett, Andrew J., Bente, Dennis A., Bergeron, Éric, Bird, Brian H., Blair, Carol D., Blasdell, Kim R., Blystad, Dag-Ragnar, Bojko, Jamie, Borth, Wayne B., Bradfute, Steven, Breyta, Rachel, Briese, Thomas, Brown, Paul A., Brown, Judith K., Buchholz, Ursula J., Buchmeier, Michael J., Bukreyev, Alexander, Burt, Felicity, Büttner, Carmen, Calisher, Charles H., Cao, Mengji, Casas, Inmaculada, Chandran, Kartik, Charrel, Rémi N., Cheng, Qi, Chiaki, Yuya, Chiapello, Marco, Choi, Il-Ryong, Ciuffo, Marina, Clegg, J. Christopher S., Crozier, Ian, Dal Bó, Elena, de la Torre, Juan Carlos, de Lamballerie, Xavier, de Swart, Rik L., Debat, Humberto, Dheilly, Nolwenn M., Di Cicco, Emiliano, Di Paola, Nicholas, Di Serio, Francesco, Dietzgen, Ralf G., Digiaro, Michele, Dolnik, Olga, Drebot, Michael A., Drexler, J. Felix, Dundon, William G., Duprex, W. Paul, Dürrwald, Ralf, Dye, John M., Easton, Andrew J., Ebihara, Hideki, Elbeaino, Toufic, Ergünay, Koray, Ferguson, Hugh W., Fooks, Anthony R., Forgia, Marco, Formenty, Pierre B. H., Fránová, Jana, Freitas-Astúa, Juliana, Fu, Jingjing, Fürl, Stephanie, Gago-Zachert, Selma, Gāo, George Fú, García, María Laura, García-Sastre, Adolfo, Garrison, Aura R., Gaskin, Thomas, Gonzalez, Jean-Paul J., Griffiths, Anthony, Goldberg, Tony L., Groschup, Martin H., Günther, Stephan, Hall, Roy A., Hammond, John, Han, Tong, Hepojoki, Jussi, Hewson, Roger, Hong, Jiang, Hong, Ni, Hongo, Seiji, Horie, Masayuki, Hu, John S., Hu, Tao, Hughes, Holly R., Hüttner, Florian, Hyndman, Timothy H., Ilyas, M., Jalkanen, Risto, Jiāng, Dàohóng, Jonson, Gilda B., Junglen, Sandra, Kadono, Fujio, Kaukinen, Karia H., Kawate, Michael, Klempa, Boris, Klingström, Jonas, Kobinger, Gary, Koloniuk, Igor, Kondō, Hideki, Koonin, Eugene V., Krupovic, Mart, Kubota, Kenji, Kurath, Gael, Laenen, Lies, Lambert, Amy J., Langevin, Stanley L., Lee, Benhur, Lefkowitz, Elliot J., Leroy, Eric M., Li, Shaorong, Li, Longhui, Lǐ, Jiànróng, Liu, Huazhen, Lukashevich, Igor S., Maes, Piet, de Souza, William Marciel, Marklewitz, Marco, Marshall, Sergio H., Marzano, Shin-Yi L., Massart, Sebastien, McCauley, John W., Melzer, Michael, Mielke-Ehret, Nicole, Miller, Kristina M., Ming, Tobi J., Mirazimi, Ali, Mordecai, Gideon J., Mühlbach, Hans-Peter, Mühlberger, Elke, Naidu, Rayapati, Natsuaki, Tomohide, Navarro, José A., Netesov, Sergey V., Neumann, Gabriele, Nowotny, Norbert, Nunes, Márcio R. T., Olmedo-Velarde, Alejandro, Palacios, Gustavo, Pallás, Vicente, Pályi, Bernadett, Papa, Anna, Paraskevopoulou, Sofia, Park, Adam C., Parrish, Colin R., Patterson, David A., Pauvolid-Corrêa, Alex, Pawęska, Janusz T., Payne, Susan, Peracchio, Carlotta, Pérez, Daniel R., Postler, Thomas S., Qi, Liying, Radoshitzky, Sheli R., Resende, Renato O., Reyes, Carina A., Rima, Bertus K., Luna, Gabriel Robles, Romanowski, Víctor, Rota, Paul, Rubbenstroth, Dennis, Rubino, Luisa, Runstadler, Jonathan A., Sabanadzovic, Sead, Sall, Amadou Alpha, Salvato, Maria S., Sang, Rosemary, Sasaya, Takahide, Schulze, Angela D., Schwemmle, Martin, Shi, Mang, Shí, Xiǎohóng, Shí, Zhènglì, Shimomoto, Yoshifumi, Shirako, Yukio, Siddell, Stuart G., Simmonds, Peter, Sironi, Manuela, Smagghe, Guy, Smither, Sophie, Song, Jin-Won, Spann, Kirsten, Spengler, Jessica R., Stenglein, Mark D., Stone, David M., Sugano, Jari, Suttle, Curtis A., Tabata, Amy, Takada, Ayato, Takeuchi, Shigeharu, Tchouassi, David P., Teffer, Amy, Tesh, Robert B., Thornburg, Natalie J., Tomitaka, Yasuhiro, Tomonaga, Keizō, Tordo, Noël, Torto, Baldwyn, Towner, Jonathan S., Tsuda, Shinya, Tu, Changchun, Turina, Massimo, Tzanetakis, Ioannis E., Uchida, Janice, Usugi, Tomio, Vaira, Anna Maria, Vallino, Marta, van den Hoogen, Bernadette, Varsani, Arvind, Vasilakis, Nikos, Verbeek, Martin, von Bargen, Susanne, Wada, Jiro, Wahl, Victoria, Walker, Peter J., Wang, Lin-Fa, Wang, Guoping, Wang, Yanxiang, Wang, Yaqin, Waqas, Muhammad, Wèi, Tàiyún, Wen, Shaohua, Whitfield, Anna E., Williams, John V., Wolf, Yuri I., Wu, Jiangxiang, Xu, Lei, Yanagisawa, Hironobu, Yang, Caixia, Yang, Zuokun, Zerbini, F. Murilo, Zhai, Lifeng, Zhang, Yong-Zhen, Zhang, Song, Zhang, Jinguo, Zhang, Zhe, and Zhou, Xueping
- Published
- 2021
- Full Text
- View/download PDF
9. Low-Input, High-Resolution 5′ Terminal Filovirus RNA Sequencing with ViBE-Seq.
- Author
-
Ross, Stephen J., Hume, Adam J., Olejnik, Judith, Turcinovic, Jacquelyn, Honko, Anna N., McKay, Lindsay G. A., Connor, John H., Griffiths, Anthony, Mühlberger, Elke, and Cifuentes, Daniel
- Subjects
MARBURG virus ,RNA sequencing ,EBOLA virus ,NUCLEOTIDE sequencing ,RNA viruses - Abstract
Although next-generation sequencing (NGS) has been instrumental in determining the genomic sequences of emerging RNA viruses, de novo sequence determination often lacks sufficient coverage of the 5′ and 3′ ends of the viral genomes. Since the genome ends of RNA viruses contain the transcription and genome replication promoters that are essential for viral propagation, a lack of terminal sequence information hinders the efforts to study the replication and transcription mechanisms of emerging and re-emerging viruses. To circumvent this, we have developed a novel method termed ViBE-Seq (Viral Bona Fide End Sequencing) for the high-resolution sequencing of filoviral genome ends using a simple yet robust protocol with high fidelity. This technique allows for sequence determination of the 5′ end of viral RNA genomes and mRNAs with as little as 50 ng of total RNA. Using the Ebola virus and Marburg virus as prototypes for highly pathogenic, re-emerging viruses, we show that ViBE-Seq is a reliable technique for rapid and accurate 5′ end sequencing of filovirus RNA sourced from virions, infected cells, and tissue obtained from infected animals. We also show that ViBE-Seq can be used to determine whether distinct reverse transcriptases have terminal deoxynucleotidyl transferase activity. Overall, ViBE-Seq will facilitate the access to complete sequences of emerging viruses. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
10. Palladium nanoparticle deposition on spherical carbon supports for heterogeneous catalysis in continuous flow.
- Author
-
Boyall, Sarah L., Berman, Phoebe, Griffiths, Anthony, Massey, Alexander, Dixon, Thomas, Shaw, Thomas, Miller, Joanna, White, Jonathan P., Menzel, Robert, Leslie, Kevin, Clemens, Graeme, Muller, Frans L., Bourne, Richard A., and Chamberlain, Thomas W.
- Published
- 2024
- Full Text
- View/download PDF
11. Design and characterization of protective pan-ebolavirus and pan-filovirus bispecific antibodies.
- Author
-
Wirchnianski, Ariel S., Nyakatura, Elisabeth K., Herbert, Andrew S., Kuehne, Ana I., Abbasi, Shawn A., Florez, Catalina, Storm, Nadia, McKay, Lindsay G. A., Dailey, Leandrew, Kuang, Erin, Abelson, Dafna M., Wec, Anna Z., Chakraborti, Srinjoy, Holtsberg, Frederick W., Shulenin, Sergey, Bornholdt, Zachary A., Aman, M. Javad, Honko, Anna N., Griffiths, Anthony, and Dye, John M.
- Subjects
BISPECIFIC antibodies ,MARBURG virus ,EBOLA virus ,HEMORRHAGIC fever ,FILOVIRIDAE ,PROTEIN engineering - Abstract
Monoclonal antibodies (mAbs) are an important class of antiviral therapeutics. MAbs are highly selective, well tolerated, and have long in vivo half-life as well as the capacity to induce immune-mediated virus clearance. Their activities can be further enhanced by integration of their variable fragments (Fvs) into bispecific antibodies (bsAbs), affording simultaneous targeting of multiple epitopes to improve potency and breadth and/or to mitigate against viral escape by a single mutation. Here, we explore a bsAb strategy for generation of pan-ebolavirus and pan-filovirus immunotherapeutics. Filoviruses, including Ebola virus (EBOV), Sudan virus (SUDV), and Marburg virus (MARV), cause severe hemorrhagic fever. Although there are two FDA-approved mAb therapies for EBOV infection, these do not extend to other filoviruses. Here, we combine Fvs from broad ebolavirus mAbs to generate novel pan-ebolavirus bsAbs that are potently neutralizing, confer protection in mice, and are resistant to viral escape. Moreover, we combine Fvs from pan-ebolavirus mAbs with those of protective MARV mAbs to generate pan-filovirus protective bsAbs. These results provide guidelines for broad antiviral bsAb design and generate new immunotherapeutic candidates. Author summary: Filoviruses, such as Ebola virus and Marburg virus (EBOV and MARV, respectively), cause severe hemorrhagic fever with a high mortality rate in humans. Monoclonal antibodies (mAbs) are effective treatments for filovirus infection, but current therapies have limited breadth. Furthermore, a single mAb is susceptible to development of resistance. Here, we used protein engineering to create "bispecific" antibodies in which activities of two different mAbs were combined into one. These bispecific antibodies had broad activity, in one case providing protection against lethal challenge by two distant clades of filoviruses (EBOV and MARV). The bispecific antibodies were also less susceptible to resistance mutations. This work provides a roadmap for development of new bispecific antibody therapies for filoviruses. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
12. Extending the In Vivo Residence Time of Macrophage Membrane‐Coated Nanoparticles through Genetic Modification.
- Author
-
Duan, Yaou, Zhou, Jiarong, Zhou, Zhidong, Zhang, Edward, Yu, Yiyan, Krishnan, Nishta, Silva‐Ayala, Daniela, Fang, Ronnie H., Griffiths, Anthony, Gao, Weiwei, and Zhang, Liangfang
- Published
- 2023
- Full Text
- View/download PDF
13. Monovalent SARS-COV-2 mRNA vaccine using optimal UTRs and LNPs is highly immunogenic and broadly protective against Omicron variants.
- Author
-
Zhongfeng Ye, Bonam, Srinivasa Reddy, McKay, Lindsay G. A., Plante, Jessica A., Walker, Jordyn, Yu Zhao, Changfeng Huang, Jinjin Chen, Chutian Xu, Yamin Li, Lihan Liu, Harmon, Joseph, Shuliang Gao, Donghui Song, Zhibo Zhang, Plante, Kenneth S., Griffiths, Anthony, Jianzhu Chen, Haitao Hu, and Qiaobing Xu
- Subjects
SARS-CoV-2 ,SARS-CoV-2 Omicron variant ,COVID-19 vaccines ,HUMORAL immunity - Abstract
The emergence of highly transmissible severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern (VOCs) that are resistant to the current COVID-19 vaccines highlights the need for continued development of broadly protective vaccines for the future. Here, we developed two messenger RNA (mRNA)-lipid nanoparticle (LNP) vaccines, TU88mCSA and ALCmCSA, using the ancestral SARS-CoV-2 spike sequence, optimized 5' and 3' untranslated regions (UTRs), and LNP combinations. Our data showed that these nanocomplexes effectively activate CD4
+ and CD8+ T cell responses and humoral immune response and provide complete protection against WA1/2020, Omicron BA.1 and BQ.1 infection in hamsters. Critically, in Omicron BQ.1 challenge hamster models, TU88mCSA and ALCmCSA not only induced robust control of virus load in the lungs but also enhanced protective efficacy in the upper respiratory airways. Antigen-specific immune analysis in mice revealed that the observed cross-protection is associated with superior UTRs [Carboxylesterase 1d (Ces1d)/adaptor protein-3β (AP3B1)] and LNP formulations that elicit robust lung tissue-resident memory T cells. Strong protective effects of TU88mCSA or ALCmCSA against both WA1/2020 and VOCs suggest that this mRNA-LNP combination can be a broadly protective vaccine platform in which mRNA cargo uses the ancestral antigen sequence regardless of the antigenic drift. This approach could be rapidly adapted for clinical use and timely deployment of vaccines against emerging and reemerging VOCs. [ABSTRACT FROM AUTHOR]- Published
- 2023
- Full Text
- View/download PDF
14. MOF-based heterogeneous catalysis in continuous flow via incorporation onto polymer-based spherical activated carbon supports.
- Author
-
Griffiths, Anthony, Boyall, Sarah L., Müller, Pia, Harrington, John P., Sobolewska, Anna M., Reynolds, William R., Bourne, Richard A., Wu, Kejun, Collins, Sean M., Muldowney, Mark, and Chamberlain, Thomas W.
- Published
- 2023
- Full Text
- View/download PDF
15. Amine-modified polyionic liquid supports enhance the efficacy of PdNPs for the catalytic hydrogenation of CO2 to formate.
- Author
-
Paterson, Reece, Fahy, Luke E., Arca, Elisabetta, Dixon, Casey, Wills, Corinne Y., Yan, Han, Griffiths, Anthony, Collins, Sean M., Wu, Kejun, Bourne, Richard A., Chamberlain, Thomas W., Knight, Julian G., and Doherty, Simon
- Subjects
CATALYTIC hydrogenation ,POLYMERIZED ionic liquids ,CONDUCTING polymers ,IONIC liquids ,BENZYLAMINE - Abstract
Palladium nanoparticles stabilised by aniline modified polymer immobilised ionic liquid is a remarkably active catalyst for the hydrogenation of CO
2 to formate; the initial TOF of 500 h−1 is markedly higher than either unmodified catalyst or its benzylamine and N,N-dimethylaniline modified counterparts and is among the highest to be reported for a PdNP-based catalyst. [ABSTRACT FROM AUTHOR]- Published
- 2023
- Full Text
- View/download PDF
16. Continuing decline of the common brushtail possum in central Australia.
- Author
-
McDonald, Peter J., Portelli, Dean J., Schubert, Andrew T., Stewart, Alistair J., and Griffiths, Anthony D.
- Subjects
GLOBAL warming ,BIOLOGICAL extinction ,ARID regions ,HIGH temperatures ,NATIONAL parks & reserves - Abstract
Australia's recent mammal declines have been most severe in the arid regions, with at least 14 species extinctions occurring therein. The common brushtail possum (Trichosurus vulpecula) is a semi-arboreal marsupial that historically occurred widely across arid Australia but has disappeared from much of this region. We surveyed the last known sites for the species in central Australia. In 2012, we detected possum scats from 3 of 19 sites in Tjoritja National Park in the Northern Territory. Presence sites were separated by <4 km and characterised by extreme ruggedness. Further scat surveys in 2016–17, and 10 499 camera-trap nights of targeted survey in 2020–21, resulted in no possum detections. Moreover, no possums were detected during >60 000 camera-trap nights at nearby monitoring sites targeting other species in 2016–22. The contraction of common brushtail possums to rugged refuges by 2012 is consistent with a decline driven by mammalian predators. The possible extirpation also coincided with or followed record years of high temperatures. The culturally significant common brushtail possum is a priority candidate species for reintroduction to parts of central Australia. Reintroduction attempts must manage mammalian predators and consider the suitability of source populations and translocation sites in the face of a rapidly warming climate. We surveyed the last known sites for the common brushtail possum in central Australia. Our data suggest that possums were extirpated from their last refuges in the MacDonnell Ranges after 2012. Any reintroduction attempts must manage mammalian predators and consider the suitability of source populations and translocation sites in the face of a rapidly warming climate. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
17. Amino‐Modified Polymer Immobilized Ionic Liquid Stabilized Ruthenium Nanoparticles: Efficient and Selective Catalysts for the Partial and Complete Reduction of Quinolines.
- Author
-
Alharbi, Adhwa A., Wills, Corinne, Chamberlain, Thomas W., Bourne, Richard A., Griffiths, Anthony, Collins, Sean M., Wu, Kejun, Mueller, Pia, Knight, Julian G., and Doherty, Simon
- Subjects
QUINOLINE ,CONDUCTING polymers ,PLATINUM nanoparticles ,IONIC liquids ,RUTHENIUM ,HETEROGENEOUS catalysts ,CATALYSTS - Abstract
RuNPs stabilised by amino‐decorated imidazolium‐based polymer immobilized ionic liquids catalyse the dimethylamine borane mediated reduction of quinolines to 1,2‐dihydroquinoline (DHQ) and 1,2,3,4‐tetrahydroquinoline (THQ). Partial reduction of 3‐substituted quinolines to the corresponding 1,2‐dihydroquinoline was achieved with 100 % selectivity in toluene under mild conditions. This is the first report of the selective partial reduction of 3‐substituted quinolines to the corresponding 1,2‐dihydroquinolines with a heterogeneous nanoparticle‐based catalyst. A wide range of substituted quinolines have also been reduced to the corresponding 1,2,3,4‐tetrahydroquinoline with high selectivity and good yields by adjusting the reaction time. The 1,2‐dihydroquinolines readily release dihydrogen in toluene at 60 °C in the absence of catalyst with no evidence for disproportionation and as such are potential organo‐hydride reagents. The initial TOF of 610 mol quinoline converted mol Ru−1 h−1 for the reduction of quinoline is among the highest to be reported for a metal nanoparticle‐based catalyst and the conversion of 96 % obtained after 4 h at 65 °C is significantly higher than its platinum nanoparticle counterpart PtNP@NH2‐PEGPIILS as well as 5 wt/% Ru/C, which only reached 9 % and 11 % conversion, respectively, at the same time. Hot filtration experiments showed that the active species was heterogeneous. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
18. A pan-variant mRNA-LNP T cell vaccine protects HLA transgenic mice from mortality after infection with SARS-CoV-2 Beta.
- Author
-
Carter, Brandon, Pinghan Huang, Ge Liu, Yuejin Liang, Lin, Paulo J. C., Bi-Hung Peng, McKay, Lindsay G. A., Dimitrakakis, Alexander, Hsu, Jason, Tat, Vivian, Saenkham-Huntsinger, Panatda, Jinjin Chen, Kaseke, Clarety, Gaiha, Gaurav D., Qiaobing Xu, Griffiths, Anthony, Tam, Ying K., Tseng, Chien-Te K., and Gifford, David K.
- Subjects
T cells ,TRANSGENIC mice ,POST-acute COVID-19 syndrome ,SARS-CoV-2 ,VACCINE effectiveness - Abstract
Licensed COVID-19 vaccines ameliorate viral infection by inducing production of neutralizing antibodies that bind the SARS-CoV-2 Spike protein and inhibit viral cellular entry. However, the clinical effectiveness of these vaccines is transitory as viral variants escape antibody neutralization. Effective vaccines that solely rely upon a T cell response to combat SARS-CoV-2 infection could be transformational because they can utilize highly conserved short pan-variant peptide epitopes, but a mRNA-LNP T cell vaccine has not been shown to provide effective anti-SARS-CoV-2 prophylaxis. Here we show a mRNA-LNP vaccine (MIT-T-COVID) based on highly conserved short peptide epitopes activates CD8+ and CD4+ T cell responses that attenuate morbidity and prevent mortality in HLA-A*02:01 transgenic mice infected with SARS-CoV-2 Beta (B.1.351). We found CD8+ T cells in mice immunized with MIT-T-COVID vaccine significantly increased from 1.1% to 24.0% of total pulmonary nucleated cells prior to and at 7 days post infection (dpi), respectively, indicating dynamic recruitment of circulating specific T cells into the infected lungs. Mice immunized with MIT-T-COVID had 2.8 (2 dpi) and 3.3 (7 dpi) times more lung infiltrating CD8+ T cells than unimmunized mice. Mice immunized with MIT-T-COVID had 17.4 times more lung infiltrating CD4+ T cells than unimmunized mice (7 dpi). The undetectable specific antibody response in MIT-T-COVID-immunized mice demonstrates specific T cell responses alone can effectively attenuate the pathogenesis of SARS-CoV-2 infection. Our results suggest further study is merited for pan-variant T cell vaccines, including for individuals that cannot produce neutralizing antibodies or to help mitigate Long COVID. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
19. The variable conversion of neutralizing anti-SARS-CoV-2 single-chain antibodies to IgG provides insight into RBD epitope accessibility.
- Author
-
Chang, Matthew R, Ke, Hanzhong, Miguéns, Laura Losada, Coherd, Christian, Nguyen, Katrina, Kamkaew, Maliwan, Johnson, Rebecca, Storm, Nadia, Honko, Anna, Zhu, Quan, Griffiths, Anthony, and Marasco, Wayne A
- Subjects
IMMUNOGLOBULINS ,MONOCLONAL antibodies ,IMMUNOGLOBULIN G ,RESPIRATORY syncytial virus infections ,SARS-CoV-2 Omicron variant ,COVID-19 pandemic ,CHILD patients - Abstract
Monoclonal antibody (mAb) therapies have rapidly become a powerful class of therapeutics with applications covering a diverse range of clinical indications. Though most widely used for the treatment of cancer, mAbs are also playing an increasing role in the defense of viral infections, most recently with palivizumab for prevention and treatment of severe RSV infections in neonatal and pediatric populations. In addition, during the COVID-19 pandemic, mAbs provided a bridge to the rollout of vaccines; however, their continued role as a therapeutic option for those at greatest risk of severe disease has become limited due to the emergence of neutralization resistant Omicron variants. Although there are many techniques for the identification of mAbs, including single B cell cloning and immunization of genetically engineered mice, the low cost, rapid throughput and technological simplicity of antibody phage display has led to its widespread adoption in mAb discovery efforts. Here we used our 27-billion-member naïve single-chain antibody (scFv) phage library to identify a panel of neutralizing anti-SARS-CoV-2 scFvs targeting diverse epitopes on the receptor binding domain (RBD). Although typically a routine process, we found that upon conversion to IgG, a number of our most potent clones failed to maintain their neutralization potency. Kinetic measurements confirmed similar affinity to the RBD; however, mechanistic studies provide evidence that the loss of neutralization is a result of structural limitations likely arising from initial choice of panning antigen. Thus this work highlights a risk of scFv-phage panning to mAb conversion and the importance of initial antigen selection. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
20. Generation of Multiple Arbovirus-like Particles Using a Rapid Recombinant Vaccinia Virus Expression Platform.
- Author
-
Wang, Yuxiang, Griffiths, Anthony, Brackney, Douglas E., and Verardi, Paulo H.
- Subjects
VACCINIA ,RECOMBINANT viruses ,ARBOVIRUS diseases ,VIRUS-like particles ,TRANSMISSION electron microscopy ,ZIKA virus ,MOSQUITO control - Abstract
As demonstrated by the 2015 Zika virus outbreak in the Americas, emerging and re-emerging arboviruses are public health threats that warrant research investment for the development of effective prophylactics and therapeutics. Many arboviral diseases are underreported, neglected, or of low prevalence, yet they all have the potential to cause outbreaks of local and international concern. Here, we show the production of virus-like particles (VLPs) using a rapid and efficient recombinant vaccinia virus (VACV) expression system for five tick- and mosquito-borne arboviruses: Powassan virus (POWV), Heartland virus (HRTV), severe fever with thrombocytopenia syndrome virus (SFTSV), Bourbon virus (BRBV) and Mayaro virus (MAYV). We detected the expression of arbovirus genes of interest by Western blot and observed the expression of VLPs that resemble native virions under transmission electron microscopy. We were also able to improve the secretion of POWV VLPs by modifying the signal sequence within the capsid gene. This study describes the use of a rapid VACV platform for the production and purification of arbovirus VLPs that can be used as subunit or vectored vaccines, and provides insights into the selection of arbovirus genes for VLP formation and genetic modifications to improve VLP secretion and yield. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
21. Anti-SARS-CoV-2 Activity of Adamantanes In Vitro and in Animal Models of Infection.
- Author
-
Lim, Sun-Young, Guo, Zhiru, Liu, Ping, McKay, Lindsay G. A., Storm, Nadia, Griffiths, Anthony, Qu, Ming Da, Finberg, Robert W., Somasundaran, Mohan, and Wang, Jennifer P.
- Subjects
COVID-19 pandemic ,PREVENTIVE medicine ,INFLUENZA A virus ,SARS disease ,AMANTADINE - Abstract
Coronavirus disease 2019 (COVID-19) has had devastating effects worldwide, with particularly high morbidity and mortality in outbreaks on residential care facilities. Amantadine, originally licensed as an antiviral agent for therapy and prophylaxis against influenza A virus, has beneficial effects on patients with Parkinson's disease and is used for treatment of Parkinson's disease, multiple sclerosis, acquired brain injury, and various other neurological disorders. Recent observational data suggest an inverse relationship between the use of amantadine and COVID-19. Adamantanes, including amantadine and rimantadine, are reported to have in vitro activity against severe acute respiratory syndrome coronavirus (SARS-CoV) and, more recently, SARS-CoV-2. We hypothesized that adamantanes have antiviral activity against SARS-CoV-2, including variant strains. To assess the activity of adamantanes against SARS-CoV-2, we used in vitro and in vivo models of infection. We established that amantadine, rimantadine, and tromantadine inhibit the growth of SARS-CoV-2 in vitro in cultured human epithelial cells. While neither rimantadine nor amantadine reduces lung viral titers in mice infected with mouse-adapted SARS-CoV-2, rimantadine significantly reduces viral titers in the lungs in golden Syrian hamsters infected with SARS-CoV-2. In summary, rimantadine has antiviral activity against SARS-CoV-2 in human alveolar epithelial cells and in the hamster model of SARS-CoV-2 lung infection. The evaluation of amantadine or rimantadine in human randomized controlled trials can definitively address applications for the treatment or prevention of COVID-19. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
22. An introduction to the Marburg virus vaccine consortium, MARVAC.
- Author
-
Cross, Robert W., Longini, Ira M., Becker, Stephan, Bok, Karin, Boucher, David, Carroll, Miles W., Díaz, Janet V., Dowling, William E., Draghia-Akli, Ruxandra, Duworko, James T., Dye, John M., Egan, Michael A., Fast, Patricia, Finan, Amy, Finch, Courtney, Fleming, Thomas R., Fusco, Joan, Geisbert, Thomas W., Griffiths, Anthony, and Günther, Stephan
- Subjects
MARBURG virus ,VIRAL vaccines ,CONSORTIA ,VACCINE development ,COMMUNICABLE diseases - Abstract
The emergence of Marburg virus (MARV) in Guinea and Ghana triggered the assembly of the MARV vaccine "MARVAC" consortium representing leaders in the field of vaccine research and development aiming to facilitate a rapid response to this infectious disease threat. Here, we discuss current progress, challenges, and future directions for MARV vaccines. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
23. Development of a Well-Characterized Cynomolgus Macaque Model of Sudan Virus Disease for Support of Product Development.
- Author
-
Alfson, Kendra J., Goez-Gazi, Yenny, Gazi, Michal, Chou, Ying-Liang, Niemuth, Nancy A., Mattix, Marc E., Staples, Hilary, Klaffke, Benjamin, Rodriguez, Gloria F., Escareno, Priscilla, Bartley, Carmen, Ticer, Anysha, Clemmons, Elizabeth A., Dutton III, John W., Griffiths, Anthony, Meister, Gabe T., Sanford, Daniel C., Cirimotich, Chris M., and Carrion Jr., Ricardo
- Subjects
VIRUS diseases ,MACAQUES ,NEW product development ,PARTIAL thromboplastin time ,CLINICAL chemistry - Abstract
The primary objective of this study was to characterize the disease course in cynomolgus macaques exposed to Sudan virus (SUDV), to determine if infection in this species is an appropriate model for the evaluation of filovirus countermeasures under the FDA Animal Rule. Sudan virus causes Sudan virus disease (SVD), with an average case fatality rate of approximately 50%, and while research is ongoing, presently there are no approved SUDV vaccines or therapies. Well characterized animal models are crucial for further developing and evaluating countermeasures for SUDV. Twenty (20) cynomolgus macaques were exposed intramuscularly to either SUDV or sterile phosphate-buffered saline; 10 SUDV-exposed animals were euthanized on schedule to characterize pathology at defined durations post-exposure and 8 SUDV-exposed animals were not part of the scheduled euthanasia cohort. Survival was assessed, along with clinical observations, body weights, body temperatures, hematology, clinical chemistry, coagulation, viral load (serum and tissues), macroscopic observations, and histopathology. There were statistically significant differences between SUDV-exposed animals and mock-exposed animals for 26 parameters, including telemetry body temperature, clinical chemistry parameters, hematology parameters, activated partial thromboplastin time, serum viremia, and biomarkers that characterize the disease course of SUDV in cynomolgus macaques. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
24. BDA‐410 inhibits SARS‐CoV‐2 main protease activity and viral replication in mammalian cells.
- Author
-
Schwake, Christopher, McKay, Lindsay, Griffiths, Anthony, Scartelli, Christina, Flaumenhaft, Robert, and Chishti, Athar H.
- Subjects
CALPAIN ,SARS-CoV-2 ,VIRAL replication - Abstract
There is a precedent in using calpain inhibitors II and XII against SARS-CoV-2 3CLpro.8 BDA-410 (Mitsubishi Pharma) is a cysteine protease inhibitor that was originally developed as a relatively selective inhibitor of calpain-1 cysteine protease activity. Of note, our demonstration of BDA-410 as a potent inhibitor of SARS-CoV-2 cysteine protease activity and viral replication was originally peer reviewed prior to the disclosure of nirmatrelvir as a cysteine protease inhibitor. Keywords: BDA-410; Calpain-1; COVID-19; SARS-CoV-2 EN BDA-410 Calpain-1 COVID-19 SARS-CoV-2 5095 5098 4 10/13/22 20221001 NES 221001 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a novel highly virulent coronavirus that causes severe illness and mortality in certain patients. BDA-410 inhibits SARS-CoV-2 main protease activity and viral replication in mammalian cells. [Extracted from the article]
- Published
- 2022
- Full Text
- View/download PDF
25. Development of a Well-Characterized Cynomolgus Macaque Model of Marburg Virus Disease for Support of Vaccine and Therapy Development.
- Author
-
Alfson, Kendra J., Goez-Gazi, Yenny, Gazi, Michal, Chou, Ying-Liang, Niemuth, Nancy A., Mattix, Marc E., Staples, Hilary M., Klaffke, Benjamin, Rodriguez, Gloria F., Bartley, Carmen, Ticer, Anysha, Clemmons, Elizabeth A., Dutton III, John W., Griffiths, Anthony, Meister, Gabe T., Sanford, Daniel C., Cirimotich, Chris M., and Carrion Jr., Ricardo
- Subjects
MARBURG virus ,VIRUS diseases ,VACCINE development ,MACAQUES ,EBOLA virus - Abstract
Marburg virus (MARV) is a filovirus that can infect humans and nonhuman primates (NHPs), causing severe disease and death. Of the filoviruses, Ebola virus (EBOV) has been the primary target for vaccine and therapeutic development. However, MARV has an average case fatality rate of approximately 50%, the infectious dose is low, and there are currently no approved vaccines or therapies targeted at infection with MARV. The purpose of this study was to characterize disease course in cynomolgus macaques intramuscularly exposed to MARV Angola variant. There were several biomarkers that reliably correlated with MARV-induced disease, including: viral load; elevated total clinical scores; temperature changes; elevated ALT, ALP, BA, TBIL, CRP and decreased ALB values; decreased lymphocytes and platelets; and prolonged PTT. A scheduled euthanasia component also provided the opportunity to study the earliest stages of the disease. This study provides evidence for the application of this model to evaluate potential vaccines and therapies against MARV and will be valuable in improving existing models. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
26. Efficient Hydrolytic Hydrogen Evolution from Sodium Borohydride Catalyzed by Polymer Immobilized Ionic Liquid‐Stabilized Platinum Nanoparticles.
- Author
-
Doherty, Simon, Knight, Julian G., Alharbi, Hussam Y., Paterson, Reece, Wills, Corinne, Dixon, Casey, Šiller, Lidija, Chamberlain, Thomas W., Griffiths, Anthony, Collins, Sean M., Wu, Kejun, Simmons, Matthew D., Bourne, Richard A., Lovelock, Kevin R. J., and Seymour, Jake
- Subjects
SODIUM borohydride ,PLATINUM nanoparticles ,CATALYSTS ,CONDUCTING polymers ,HYDROGEN evolution reactions ,KINETIC isotope effects ,CATALYST poisoning ,HYDROGEN - Abstract
Platinum nanoparticles stabilized by imidazolium‐based phosphine‐decorated Polymer Immobilized Ionic Liquids (PPh2‐PIIL) catalyze the hydrolytic evolution of hydrogen from sodium borohydride with remarkable efficiency, under mild conditions. The composition of the polymer influences efficiency with the catalyst based on a polyethylene glycol modified imidazolium monomer (PtNP@PPh2‐PEGPIILS) more active than its N‐alkylated counterpart (PtNP@PPh2‐N‐decylPIILS). The maximum initial TOF of 169 moleH2.molcat−1.min−1 obtained at 30 °C with a catalyst loading of 0.08 mol% is among the highest to be reported for the aqueous phase hydrolysis of sodium borohydride catalyzed by a PtNP‐based system. Kinetic studies revealed that the apparent activation energy (Ea) of 23.9 kJ mol−1 for the hydrolysis of NaBH4 catalyzed by PtNP@PPh2‐PEGPIILS is significantly lower than that of 35.6 kJ mol−1 for PtNP@PPh2‐N‐decylPIILS. Primary kinetic isotope effects kH/kD of 1.8 and 2.1 obtained with PtNP@PPh2‐PEGPIILS and PtNP@PPh2‐N‐decylPIILS, respectively, for the hydrolysis with D2O support a mechanism involving rate determining oxidative addition or σ‐bond metathesis of the O−H bond. Catalyst stability and reuse studies showed that PtNP@PPh2‐PEGPIILS retained 70 % of its activity across five runs; the gradual drop in conversion appears to be due to poisoning of the catalyst by the accumulated metaborate product as well as the increased viscosity of the reaction mixture. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
27. Characterization of an Anti-Ebola Virus Hyperimmune Globulin Derived From Convalescent Plasma.
- Author
-
Ciencewicki, Jonathan M, Herbert, Andrew S, Storm, Nadia, Josleyn, Nicole M, Huie, Kathleen E, McKay, Lindsay G A, Griffiths, Anthony, Dye, John M, Willis, Todd, and Arora, Vikram
- Subjects
CONVALESCENT plasma ,EBOLA virus disease ,ANTIBODY titer ,VIRUS diseases ,ENZYME-linked immunosorbent assay ,RESEARCH ,ANIMAL experimentation ,BLOOD plasma ,EVALUATION research ,EBOLA virus ,INTRAVENOUS immunoglobulins ,COMPARATIVE studies ,RESEARCH funding ,VIRAL antibodies ,MICE - Abstract
Background: Convalescent plasma has been used to treat many viral diseases including Ebola. The manufacture of a purified anti-Ebola virus (EBOV) intravenous immunoglobulin (IVIG) from pooled convalescent plasma is described in this paper.Methods: An enzyme-linked immunosorbent assay (ELISA) targeting an EBOV surface glycoprotein antigen was used to determine the immunoglobulin titer of pooled plasma and purified anti-EBOV IVIG. Anti-EBOV IVIG was also tested in neutralization assays using a vesicular stomatitis virus pseudovirion expressing EBOV glycoprotein on its surface and with live EBOV. Finally, the efficacy of the anti-EBOV IVIG was assessed in a mouse model of EBOV infection.Results: In the ELISA, the anti-EBOV IVIG was shown to have a 7-fold increase in immunoglobulin G (IgG) titer over pooled convalescent plasma. In both the pseudovirion and live virus assays, the anti-EBOV IVIG showed approximately 5- to 6-fold increased potency over pooled plasma. Anti-EBOV IVIG also significantly improved survivability in mice infected with the virus when administered concurrently or 2 days after infection.Conclusions: These data support this purified anti-EBOV IVIG merits additional investigation and clinical trials for treatment and postexposure prophylaxis of Ebola virus disease. The experience gained can be applied to manufacture hyperimmune globulins against other emerging viruses. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
28. A Modular Biomaterial Scaffold‐Based Vaccine Elicits Durable Adaptive Immunity to Subunit SARS‐CoV‐2 Antigens.
- Author
-
Langellotto, Fernanda, Dellacherie, Maxence O., Yeager, Chyenne, Ijaz, Hamza, Yu, Jingyou, Cheng, Chi‐An, Dimitrakakis, Nikolaos, Seiler, Benjamin T., Gebre, Makda S., Gilboa, Tal, Johnson, Rebecca, Storm, Nadia, Bardales, Sarai, Graveline, Amanda, White, Des, Tringides, Christina M., Cartwright, Mark J., Doherty, Edward J., Honko, Anna, and Griffiths, Anthony
- Published
- 2021
- Full Text
- View/download PDF
29. Surface Glycan Modification of Cellular Nanosponges to Promote SARS-CoV-2 Inhibition.
- Author
-
Xiangzhao Ai, Dan Wang, Anna Honko, Yaou Duan, Gavrish, Igor, Fang, Ronnie H., Griffiths, Anthony, Weiwei Gao, and Liangfang Zhang
- Published
- 2021
- Full Text
- View/download PDF
30. Biomaterials and Oxygen Join Forces to Shape the Immune Response and Boost COVID‐19 Vaccines.
- Author
-
Colombani, Thibault, Eggermont, Loek J., Rogers, Zachary J., McKay, Lindsay G. A., Avena, Laura E., Johnson, Rebecca I., Storm, Nadia, Griffiths, Anthony, and Bencherif, Sidi A.
- Subjects
COVID-19 ,COVID-19 vaccines ,EMERGING infectious diseases ,IMMUNE response ,VACCINE effectiveness ,BIOMATERIALS - Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) has led to an unprecedented global health crisis, resulting in a critical need for effective vaccines that generate protective antibodies. Protein subunit vaccines represent a promising approach but often lack the immunogenicity required for strong immune stimulation. To overcome this challenge, it is first demonstrated that advanced biomaterials can be leveraged to boost the effectiveness of SARS‐CoV‐2 protein subunit vaccines. Additionally, it is reported that oxygen is a powerful immunological co‐adjuvant and has an ability to further potentiate vaccine potency. In preclinical studies, mice immunized with an oxygen‐generating coronavirus disease 2019 (COVID‐19) cryogel‐based vaccine (O2‐CryogelVAX) exhibit a robust Th1 and Th2 immune response, leading to a sustained production of highly effective neutralizing antibodies against the virus. Even with a single immunization, O2‐CryogelVAX achieves high antibody titers within 21 days, and both binding and neutralizing antibody levels are further increased after a second dose. Engineering a potent vaccine system that generates sufficient neutralizing antibodies after one dose is a preferred strategy amid vaccine shortage. The data suggest that this platform is a promising technology to reinforce vaccine‐driven immunostimulation and is applicable to current and emerging infectious diseases. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
31. Three Meanings of 'Copyright' in British Nineteenth-Century Printmaking.
- Author
-
Griffiths, Anthony
- Abstract
The article looks at the various meanings of copyright in printmaking in Great Britain in the 19th century.
- Published
- 2021
32. Germline-encoded amino acid—binding motifs drive immunodominant public antibody responses.
- Author
-
Shrock, Ellen L., Timms, Richard T., Kula, Tomasz, Mena, Elijah L., West, Anthony P. Jr., Guo, Rui, Lee, I-Hsiu, Cohen, Alexander A., McKay, Lindsay G. A., Bi, Caihong, Keerti, Leng, Yumei, Fujimura, Eric, Horns, Felix, Li, Mamie, Wesemann, Duane R., Griffiths, Anthony, Gewurz, Benjamin E., Bjorkman, Pamela J., and Elledge, Stephen J.
- Published
- 2023
- Full Text
- View/download PDF
33. Part 1 MRCOG Synoptic Revision Guide
- Author
-
Khalil, Asma, editor and Griffiths, Anthony, editor
- Published
- 2023
- Full Text
- View/download PDF
34. Identification and Characterization of Defective Viral Genomes in Ebola Virus-Infected Rhesus Macaques.
- Author
-
Johnson, Rebecca I., Boczkowska, Beata, Alfson, Kendra, Weary, Taylor, Menzie, Heather, Delgado, Jenny, Rodriguez, Gloria, Carrion Jr., Ricardo, and Griffiths, Anthony
- Subjects
- *
RHESUS monkeys , *RNA virus infections , *EBOLA virus , *MARBURG virus , *REVERSE transcriptase , *VIRAL genomes , *SEMEN - Abstract
Ebola virus (EBOV), of the family Filoviridae, is an RNA virus that can cause a hemorrhagic fever with a high mortality rate. Defective viral genomes (DVGs) are truncated genomes that have been observed during multiple RNA virus infections, including in vitro EBOV infection, and have previously been associated with viral persistence and immunostimulatory activity. As DVGs have been detected in cells persistently infected with EBOV, we hypothesized that DVGs may also accumulate during viral replication in filovirus-infected hosts. Therefore, we interrogated sequence data from serum and tissue samples using a bioinformatics tool in order to identify the presence of DVGs in nonhuman primates (NHPs) infected with EBOV, Sudan virus (SUDV), or Marburg virus (MARV). Multiple 59 copy-back DVGs (cbDVGs) were detected in NHP serum during the acute phase of filovirus infection. While the relative abundance of total DVGs in most animals was low, serum collected during acute EBOV and SUDV infections, but not MARV infections, contained a higher proportion of short trailer sequence cbDVGs than the challenge stock. This indicated an accumulation of these DVGs throughout infection, potentially due to the preferential replication of short DVGs over the longer viral genome. Using reverse transcriptase PCR (RT-PCR) and deep sequencing, we also confirmed the presence of 59 cbDVGs in EBOV-infected NHP testes, which is of interest due to EBOV persistence in semen of male survivors of infection. This work suggests that DVGs play a role in EBOV infection in vivo and that further study will lead to a better understanding of EBOV pathogenesis. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
35. Heteroatom modified polymer immobilized ionic liquid stabilized ruthenium nanoparticles: Efficient catalysts for the hydrolytic evolution of hydrogen from sodium borohydride.
- Author
-
Paterson, Reece, Alharbi, Adhwa A., Wills, Corinne, Dixon, Casey, Šiller, Lidja, Chamberlain, Thomas W., Griffiths, Anthony, Collins, Sean M., Wu, Kejun, Simmons, Matthew D., Bourne, Richard A., Lovelock, Kevin R.J., Seymour, Jake, Knight, Julian G., and Doherty, Simon
- Subjects
- *
HETEROCHAIN polymers , *IONIC liquids , *HYDROLYSIS , *ISOTOPES , *VISCOSITY , *CATALYSTS - Abstract
• Ultrafine RuNPs are stabilised by amino-modified polymer immobilized ionic liquid. • High activity for hydrolytic evolution of hydrogen from NaBH 4. • Kinetic studies confirm the hydrolysis is first order in catalyst and hydride. • Kinetic isotope studies with H 2 O/D 2 O and NaBH 4 /NaBD 4 support the proposed mechanism. • High activity retained over five reuses with only a minor reduction in conversion. Ruthenium nanoparticles stabilised by polymer immobilized ionic liquids catalyse the hydrolytic release of hydrogen from sodium borohydride. The composition of the polymer influences performance and ruthenium nanoparticles stabilised by an amine-decorated imidazolium-based polymer immobilised ionic liquid (RuNP@NH 2 -PIILS) was the most efficient with a maximum initial turnover frequency (TOF) of 177 mole H2.mol Ru −1.min−1, obtained at 30°C with a catalyst loading of 0.08 mol%; markedly higher than that of 69 mol H2.mol Ru −1.min−1 obtained with 5 wt% Ru/C and one of the highest to be reported for a RuNP catalyst. The apparent activation energy (Ea) of 38.9 kJ mol−1 for the hydrolysis of NaBH 4 catalysed by RuNP@NH 2 -PIILS is lower than that for the other polymer immobilized ionic liquid stabilised RuNPs, which is consistent with its efficacy. Comparison of the initial rates of hydrolysis in H 2 O and D 2 O catalysed by RuNP@NH 2 -PIILS gave a primary kinetic isotope effect (k H / k D) of 2.3 which supports a mechanism involving rate limiting oxidative addition of one of the O-H bonds in a strongly hydrogen-bonded surface-coordinated [BH 3 H−]—-H 2 O ensemble. The involvement of a surface-coordinated borohydride is further supported by an inverse kinetic isotope effect of 0.65 obtained from a comparison of the initial rates for the hydrolysis of NaBH 4 and NaBD 4 under the conditions of catalysis i.e., at a high hydride/catalyst mole ratio. Interestingly though, when the comparison of the initial rates of hydrolysis of NaBH 4 and NaBD 4 was conducted in dilute solution with a hydride/catalyst mole ratio of 1 a kinetic isotope effect (k H / k D) of 2.72 was obtained; this would be more consistent with concerted activation of both an O-H and B-H bond in the rate limiting step, possibly via a concerted oxidative addition-hydride transfer in the surface-coordinated hydrogen-bonded ensemble. Catalyst stability and reuse studies showed that RuNP@NH 2 -PIILS retained 71% of its activity over five runs; the gradual drop in the initial TOF with run number appears to be due to passivation of the catalyst by the sodium borate by-product as well as an increase in viscosity of the reaction mixture rather than leaching of the catalyst. [Display omitted] [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
36. ICTV Virus Taxonomy Profile: Filoviridae 2024.
- Author
-
Biedenkopf N, Bukreyev A, Chandran K, Di Paola N, Formenty PBH, Griffiths A, Hume AJ, Mühlberger E, Netesov SV, Palacios G, Pawęska JT, Smither S, Takada A, Wahl V, and Kuhn JH
- Subjects
- Animals, Humans, Phylogeny, Genome, Viral, Virus Replication, Mammals genetics, Ebolavirus genetics, Rhabdoviridae genetics, Marburgvirus
- Abstract
Filoviridae is a family of negative-sense RNA viruses with genomes of about 13.1-20.9 kb that infect fish, mammals and reptiles. The filovirid genome is a linear, non-segmented RNA with five canonical open reading frames (ORFs) that encode a nucleoprotein (NP), a polymerase cofactor (VP35), a glycoprotein (GP
1,2 ), a transcriptional activator (VP30) and a large protein (L) containing an RNA-directed RNA polymerase (RdRP) domain. All filovirid genomes encode additional proteins that vary among genera. Several filovirids (e.g., Ebola virus, Marburg virus) are pathogenic for humans and highly virulent. This is a summary of the International Committee on Taxonomy of Viruses (ICTV) Report on the family Filoviridae , which is available at www.ictv.global/report/filoviridae.- Published
- 2024
- Full Text
- View/download PDF
37. Monovalent SARS-COV-2 mRNA vaccine using optimal UTRs and LNPs is highly immunogenic and broadly protective against Omicron variants.
- Author
-
Ye Z, Bonam SR, McKay LGA, Plante JA, Walker J, Zhao Y, Huang C, Chen J, Xu C, Li Y, Liu L, Harmon J, Gao S, Song D, Zhang Z, Plante KS, Griffiths A, Chen J, Hu H, and Xu Q
- Subjects
- Cricetinae, Animals, Humans, Mice, RNA, Messenger genetics, mRNA Vaccines, SARS-CoV-2 genetics, 3' Untranslated Regions, Antibodies, Neutralizing, Antibodies, Viral, COVID-19 Vaccines genetics, COVID-19 prevention & control
- Abstract
The emergence of highly transmissible severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern (VOCs) that are resistant to the current COVID-19 vaccines highlights the need for continued development of broadly protective vaccines for the future. Here, we developed two messenger RNA (mRNA)-lipid nanoparticle (LNP) vaccines, TU88mCSA and ALCmCSA, using the ancestral SARS-CoV-2 spike sequence, optimized 5' and 3' untranslated regions (UTRs), and LNP combinations. Our data showed that these nanocomplexes effectively activate CD4
+ and CD8+ T cell responses and humoral immune response and provide complete protection against WA1/2020, Omicron BA.1 and BQ.1 infection in hamsters. Critically, in Omicron BQ.1 challenge hamster models, TU88mCSA and ALCmCSA not only induced robust control of virus load in the lungs but also enhanced protective efficacy in the upper respiratory airways. Antigen-specific immune analysis in mice revealed that the observed cross-protection is associated with superior UTRs [Carboxylesterase 1d (Ces1d)/adaptor protein-3β (AP3B1)] and LNP formulations that elicit robust lung tissue-resident memory T cells. Strong protective effects of TU88mCSA or ALCmCSA against both WA1/2020 and VOCs suggest that this mRNA-LNP combination can be a broadly protective vaccine platform in which mRNA cargo uses the ancestral antigen sequence regardless of the antigenic drift. This approach could be rapidly adapted for clinical use and timely deployment of vaccines against emerging and reemerging VOCs., Competing Interests: Competing interests statement:Q.X. and Z.Y. are inventors on a provisional patent from Tufts University. Q.X. is a founder and consultant (with Chief Technology Officer title) of Hopewell Therapeutics Inc.- Published
- 2023
- Full Text
- View/download PDF
38. Amine-modified polyionic liquid supports enhance the efficacy of PdNPs for the catalytic hydrogenation of CO 2 to formate.
- Author
-
Paterson R, Fahy LE, Arca E, Dixon C, Wills CY, Yan H, Griffiths A, Collins SM, Wu K, Bourne RA, Chamberlain TW, Knight JG, and Doherty S
- Abstract
Palladium nanoparticles stabilised by aniline modified polymer immobilised ionic liquid is a remarkably active catalyst for the hydrogenation of CO
2 to formate; the initial TOF of 500 h-1 is markedly higher than either unmodified catalyst or its benzylamine and N , N -dimethylaniline modified counterparts and is among the highest to be reported for a PdNP-based catalyst.- Published
- 2023
- Full Text
- View/download PDF
39. Annual (2023) taxonomic update of RNA-directed RNA polymerase-encoding negative-sense RNA viruses (realm Riboviria : kingdom Orthornavirae : phylum Negarnaviricota ).
- Author
-
Kuhn JH, Abe J, Adkins S, Alkhovsky SV, Avšič-Županc T, Ayllón MA, Bahl J, Balkema-Buschmann A, Ballinger MJ, Kumar Baranwal V, Beer M, Bejerman N, Bergeron É, Biedenkopf N, Blair CD, Blasdell KR, Blouin AG, Bradfute SB, Briese T, Brown PA, Buchholz UJ, Buchmeier MJ, Bukreyev A, Burt F, Büttner C, Calisher CH, Cao M, Casas I, Chandran K, Charrel RN, Kumar Chaturvedi K, Chooi KM, Crane A, Dal Bó E, Carlos de la Torre J, de Souza WM, de Swart RL, Debat H, Dheilly NM, Di Paola N, Di Serio F, Dietzgen RG, Digiaro M, Drexler JF, Duprex WP, Dürrwald R, Easton AJ, Elbeaino T, Ergünay K, Feng G, Firth AE, Fooks AR, Formenty PBH, Freitas-Astúa J, Gago-Zachert S, Laura García M, García-Sastre A, Garrison AR, Gaskin TR, Gong W, Gonzalez JJ, de Bellocq J, Griffiths A, Groschup MH, Günther I, Günther S, Hammond J, Hasegawa Y, Hayashi K, Hepojoki J, Higgins CM, Hongō S, Horie M, Hughes HR, Hume AJ, Hyndman TH, Ikeda K, Jiāng D, Jonson GB, Junglen S, Klempa B, Klingström J, Kondō H, Koonin EV, Krupovic M, Kubota K, Kurath G, Laenen L, Lambert AJ, Lǐ J, Li JM, Liu R, Lukashevich IS, MacDiarmid RM, Maes P, Marklewitz M, Marshall SH, Marzano SL, McCauley JW, Mirazimi A, Mühlberger E, Nabeshima T, Naidu R, Natsuaki T, Navarro B, Navarro JA, Neriya Y, Netesov SV, Neumann G, Nowotny N, Nunes MRT, Ochoa-Corona FM, Okada T, Palacios G, Pallás V, Papa A, Paraskevopoulou S, Parrish CR, Pauvolid-Corrêa A, Pawęska JT, Pérez DR, Pfaff F, Plemper RK, Postler TS, Rabbidge LO, Radoshitzky SR, Ramos-González PL, Rehanek M, Resende RO, Reyes CA, Rodrigues TCS, Romanowski V, Rubbenstroth D, Rubino L, Runstadler JA, Sabanadzovic S, Sadiq S, Salvato MS, Sasaya T, Schwemmle M, Sharpe SR, Shi M, Shimomoto Y, Kavi Sidharthan V, Sironi M, Smither S, Song JW, Spann KM, Spengler JR, Stenglein MD, Takada A, Takeyama S, Tatara A, Tesh RB, Thornburg NJ, Tian X, Tischler ND, Tomitaka Y, Tomonaga K, Tordo N, Tu C, Turina M, Tzanetakis IE, Maria Vaira A, van den Hoogen B, Vanmechelen B, Vasilakis N, Verbeek M, von Bargen S, Wada J, Wahl V, Walker PJ, Waltzek TB, Whitfield AE, Wolf YI, Xia H, Xylogianni E, Yanagisawa H, Yano K, Ye G, Yuan Z, Zerbini FM, Zhang G, Zhang S, Zhang YZ, Zhao L, and Økland AL
- Subjects
- RNA-Dependent RNA Polymerase genetics, Negative-Sense RNA Viruses, RNA Viruses genetics
- Abstract
In April 2023, following the annual International Committee on Taxonomy of Viruses (ICTV) ratification vote on newly proposed taxa, the phylum Negarnaviricota was amended and emended. The phylum was expanded by one new family, 14 new genera, and 140 new species. Two genera and 538 species were renamed. One species was moved, and four were abolished. This article presents the updated taxonomy of Negarnaviricota as now accepted by the ICTV.
- Published
- 2023
- Full Text
- View/download PDF
40. The variable conversion of neutralizing anti-SARS-CoV-2 single-chain antibodies to IgG provides insight into RBD epitope accessibility.
- Author
-
Chang MR, Ke H, Losada Miguéns L, Coherd C, Nguyen K, Kamkaew M, Johnson R, Storm N, Honko A, Zhu Q, Griffiths A, and Marasco WA
- Subjects
- Animals, Mice, Humans, Epitopes, Pandemics, SARS-CoV-2 genetics, Antibodies, Viral, Antibodies, Monoclonal, Immunoglobulin G, Spike Glycoprotein, Coronavirus genetics, Antibodies, Neutralizing chemistry, Single-Chain Antibodies, COVID-19
- Abstract
Monoclonal antibody (mAb) therapies have rapidly become a powerful class of therapeutics with applications covering a diverse range of clinical indications. Though most widely used for the treatment of cancer, mAbs are also playing an increasing role in the defense of viral infections, most recently with palivizumab for prevention and treatment of severe RSV infections in neonatal and pediatric populations. In addition, during the COVID-19 pandemic, mAbs provided a bridge to the rollout of vaccines; however, their continued role as a therapeutic option for those at greatest risk of severe disease has become limited due to the emergence of neutralization resistant Omicron variants. Although there are many techniques for the identification of mAbs, including single B cell cloning and immunization of genetically engineered mice, the low cost, rapid throughput and technological simplicity of antibody phage display has led to its widespread adoption in mAb discovery efforts. Here we used our 27-billion-member naïve single-chain antibody (scFv) phage library to identify a panel of neutralizing anti-SARS-CoV-2 scFvs targeting diverse epitopes on the receptor binding domain (RBD). Although typically a routine process, we found that upon conversion to IgG, a number of our most potent clones failed to maintain their neutralization potency. Kinetic measurements confirmed similar affinity to the RBD; however, mechanistic studies provide evidence that the loss of neutralization is a result of structural limitations likely arising from initial choice of panning antigen. Thus this work highlights a risk of scFv-phage panning to mAb conversion and the importance of initial antigen selection., (© The Author(s) 2023. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)
- Published
- 2023
- Full Text
- View/download PDF
41. IMM-BCP-01, a patient-derived anti-SARS-CoV-2 antibody cocktail, is active across variants of concern including Omicron BA.1 and BA.2.
- Author
-
Nikitin PA, DiMuzio JM, Dowling JP, Patel NB, Bingaman-Steele JL, Heimbach BC, Henriquez N, Nicolescu C, Polley A, Sikorski EL, Howanski RJ, Nath M, Shukla H, Scheaffer SM, Finn JP, Liang LF, Smith T, Storm N, McKay LGA, Johnson RI, Malsick LE, Honko AN, Griffiths A, Diamond MS, Sarma P, Geising DH, Morin MJ, and Robinson MK
- Subjects
- Animals, Antibodies, Viral, Cricetinae, Humans, Spike Glycoprotein, Coronavirus genetics, COVID-19, SARS-CoV-2
- Abstract
Monoclonal antibodies are an efficacious therapy against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, rapid viral mutagenesis led to escape from most of these therapies, outlining the need for an antibody cocktail with a broad neutralizing potency. Using an unbiased interrogation of the memory B cell repertoire of patients with convalescent COVID-19, we identified human antibodies with broad antiviral activity in vitro and efficacy in vivo against all tested SARS-CoV-2 variants of concern, including Delta and Omicron BA.1 and BA.2. Here, we describe an antibody cocktail, IMM-BCP-01, that consists of three patient-derived broadly neutralizing antibodies directed at nonoverlapping surfaces on the SARS-CoV-2 Spike protein. Two antibodies, IMM20184 and IMM20190, directly blocked Spike binding to the ACE2 receptor. Binding of the third antibody, IMM20253, to its cryptic epitope on the outer surface of RBD altered the conformation of the Spike Trimer, promoting the release of Spike monomers. These antibodies decreased Omicron SARS-CoV-2 infection in the lungs of Syrian golden hamsters in vivo and potently induced antiviral effector response in vitro, including phagocytosis, ADCC, and complement pathway activation. Our preclinical data demonstrated that the three-antibody cocktail IMM-BCP-01 could be a promising means for preventing or treating infection of SARS-CoV-2 variants of concern, including Omicron BA.1 and BA.2, in susceptible individuals.
- Published
- 2022
- Full Text
- View/download PDF
42. Fecal Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-Cov-2) RNA Is Associated With Decreased Coronavirus Disease 2019 (COVID-19) Survival.
- Author
-
Das Adhikari U, Eng G, Farcasanu M, Avena LE, Choudhary MC, Triant VA, Flagg M, Schiff AE, Gomez I, Froehle LM, Diefenbach TJ, Ronsard L, Lingwood D, Lee GC, Rabi SA, Erstad D, Velmahos G, Li JZ, Hodin R, Stone JR, Honko AN, Griffiths A, Yilmaz ÖH, and Kwon DS
- Subjects
- Feces, Gastrointestinal Tract, Humans, RNA, Viral, COVID-19, SARS-CoV-2 genetics
- Abstract
The clinical significance of severe acute respiratory syndrome coronavirus 2 (SARS CoV-2) RNA in stool remains uncertain. We found that extrapulmonary dissemination of infection to the gastrointestinal tract, assessed by the presence of SARS-CoV-2 RNA in stool, is associated with decreased coronavirus disease 2019 (COVID-19) survival. Measurement of SARS-CoV-2 RNA in stool may have utility for clinical risk assessment., (© The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.)
- Published
- 2022
- Full Text
- View/download PDF
43. Structural basis for continued antibody evasion by the SARS-CoV-2 receptor binding domain.
- Author
-
Nabel KG, Clark SA, Shankar S, Pan J, Clark LE, Yang P, Coscia A, McKay LGA, Varnum HH, Brusic V, Tolan NV, Zhou G, Desjardins M, Turbett SE, Kanjilal S, Sherman AC, Dighe A, LaRocque RC, Ryan ET, Tylek C, Cohen-Solal JF, Darcy AT, Tavella D, Clabbers A, Fan Y, Griffiths A, Correia IR, Seagal J, Baden LR, Charles RC, and Abraham J
- Subjects
- Angiotensin-Converting Enzyme 2 chemistry, Angiotensin-Converting Enzyme 2 metabolism, BNT162 Vaccine immunology, Betacoronavirus immunology, COVID-19 immunology, COVID-19 virology, Cross Reactions, Cryoelectron Microscopy, Crystallography, X-Ray, Epitopes, Evolution, Molecular, Humans, Models, Molecular, Mutation, Polysaccharides analysis, Protein Binding, Protein Domains, Receptors, Coronavirus chemistry, Receptors, Coronavirus metabolism, SARS-CoV-2 genetics, Spike Glycoprotein, Coronavirus genetics, Viral Pseudotyping, Antibodies, Neutralizing immunology, Antibodies, Viral immunology, Immune Evasion, SARS-CoV-2 immunology, Spike Glycoprotein, Coronavirus chemistry, Spike Glycoprotein, Coronavirus immunology
- Abstract
Many studies have examined the impact of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants on neutralizing antibody activity after they have become dominant strains. Here, we evaluate the consequences of further viral evolution. We demonstrate mechanisms through which the SARS-CoV-2 receptor binding domain (RBD) can tolerate large numbers of simultaneous antibody escape mutations and show that pseudotypes containing up to seven mutations, as opposed to the one to three found in previously studied variants of concern, are more resistant to neutralization by therapeutic antibodies and serum from vaccine recipients. We identify an antibody that binds the RBD core to neutralize pseudotypes for all tested variants but show that the RBD can acquire an N-linked glycan to escape neutralization. Our findings portend continued emergence of escape variants as SARS-CoV-2 adapts to humans.
- Published
- 2022
- Full Text
- View/download PDF
44. Surface Glycan Modification of Cellular Nanosponges to Promote SARS-CoV-2 Inhibition.
- Author
-
Ai X, Wang D, Honko A, Duan Y, Gavrish I, Fang RH, Griffiths A, Gao W, and Zhang L
- Subjects
- COVID-19 virology, Heparin metabolism, Humans, Polysaccharides metabolism, Heparin administration & dosage, Nanostructures therapeutic use, Polysaccharides administration & dosage, SARS-CoV-2 metabolism, COVID-19 Drug Treatment
- Abstract
Cellular binding and entry of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are mediated by its spike glycoprotein (S protein), which binds with not only the human angiotensin-converting enzyme 2 (ACE2) receptor but also glycosaminoglycans such as heparin. Cell membrane-coated nanoparticles ("cellular nanosponges") mimic the host cells to attract and neutralize SARS-CoV-2 through natural cellular receptors, leading to a broad-spectrum antiviral strategy. Herein, we show that increasing surface heparin density on the cellular nanosponges can promote their inhibition against SARS-CoV-2. Specifically, cellular nanosponges are made with azido-expressing host cell membranes followed by conjugating heparin to the nanosponge surfaces. Cellular nanosponges with a higher heparin density have a larger binding capacity with viral S proteins and a significantly higher inhibition efficacy against SARS-CoV-2 infectivity. Overall, surface glycan engineering of host-mimicking cellular nanosponges is a facile method to enhance SARS-CoV-2 inhibition. This approach can be readily generalized to promote the inhibition of other glycan-dependent viruses.
- Published
- 2021
- Full Text
- View/download PDF
45. An AAV-based, room-temperature-stable, single-dose COVID-19 vaccine provides durable immunogenicity and protection in non-human primates.
- Author
-
Zabaleta N, Dai W, Bhatt U, Hérate C, Maisonnasse P, Chichester JA, Sanmiguel J, Estelien R, Michalson KT, Diop C, Maciorowski D, Dereuddre-Bosquet N, Cavarelli M, Gallouët AS, Naninck T, Kahlaoui N, Lemaitre J, Qi W, Hudspeth E, Cucalon A, Dyer CD, Pampena MB, Knox JJ, LaRocque RC, Charles RC, Li D, Kim M, Sheridan A, Storm N, Johnson RI, Feldman J, Hauser BM, Contreras V, Marlin R, Tsong Fang RH, Chapon C, van der Werf S, Zinn E, Ryan A, Kobayashi DT, Chauhan R, McGlynn M, Ryan ET, Schmidt AG, Price B, Honko A, Griffiths A, Yaghmour S, Hodge R, Betts MR, Freeman MW, Wilson JM, Le Grand R, and Vandenberghe LH
- Subjects
- Animals, Antibodies, Neutralizing immunology, Antibodies, Viral immunology, COVID-19 Vaccines administration & dosage, COVID-19 Vaccines genetics, Dependovirus genetics, Dependovirus metabolism, Female, Humans, Immunogenicity, Vaccine immunology, Immunologic Memory immunology, Macaca fascicularis, Macaca mulatta, Male, Mice, Mice, Inbred BALB C, Mice, Inbred C57BL, T-Lymphocytes immunology, Transgenes genetics, Vaccination methods, Viral Load immunology, Antibodies, Neutralizing blood, Antibodies, Viral blood, COVID-19 prevention & control, COVID-19 Vaccines immunology, SARS-CoV-2 immunology, Spike Glycoprotein, Coronavirus immunology
- Abstract
The SARS-CoV-2 pandemic has affected more than 185 million people worldwide resulting in over 4 million deaths. To contain the pandemic, there is a continued need for safe vaccines that provide durable protection at low and scalable doses and can be deployed easily. Here, AAVCOVID-1, an adeno-associated viral (AAV), spike-gene-based vaccine candidate demonstrates potent immunogenicity in mouse and non-human primates following a single injection and confers complete protection from SARS-CoV-2 challenge in macaques. Peak neutralizing antibody titers are sustained at 1 year and complemented by functional memory T cell responses. The AAVCOVID vector has no relevant pre-existing immunity in humans and does not elicit cross-reactivity to common AAVs used in gene therapy. Vector genome persistence and expression wanes following injection. The single low-dose requirement, high-yield manufacturability, and 1-month stability for storage at room temperature may make this technology well suited to support effective immunization campaigns for emerging pathogens on a global scale., Competing Interests: Declaration of interests J.M.W. is a paid advisor to and holds equity in Scout Bio and Passage Bio; he holds equity in Surmount Bio; he also has sponsored research agreements with Amicus Therapeutics, Biogen, Elaaj Bio, Janssen, Moderna, Passage Bio, Regeneron, Scout Bio, Surmount Bio, and Ultragenyx, which are licensees of Penn technology. J.M.W. had a sponsored research agreement with Albamunity that funded this work. He also has a sponsored research agreement with G2 Bio. L.H.V. and J.M.W. are inventors on patents that have been licensed to various biopharmaceutical companies and for which they may receive payments including vector and vaccine technologies herein described. L.H.V., W.D., U.B., N.Z. are named inventors on two patent applications relevant to AAVCOVID. W.Q., E.H., S.Y., and R.H. are employees of Novartis. M.W.F. is a paid consultant to 5AM Ventures and to Mitobridge/Astellas. L.H.V. is a paid advisor to Novartis, Akouos, and Affinia Therapeutics and serves on the Board of Directors of Affinia, Addgene, and Odylia Therapeutics. L.H.V. holds equity in Akouos and Affinia and receives sponsored research funding from Albamunity Inc. to which he is an unpaid consultant. M.R.B. receives consulting fees from Interius Biotherapeutics. R.C.L. is a subcontractor with the CDC Foundation and receives royalties from UpToDate., (Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.